Aortic cannula for ex vivo organ care system

Information

  • Patent Grant
  • 11122795
  • Patent Number
    11,122,795
  • Date Filed
    Friday, December 21, 2018
    5 years ago
  • Date Issued
    Tuesday, September 21, 2021
    3 years ago
  • CPC
  • Field of Search
    • CPC
    • A61N1/0236
    • A61N1/0242
    • A61N1/0247
    • A61M1/00
    • A61M2210/125
    • A61M2210/127
    • A61F2/24
  • International Classifications
    • A01N1/02
Abstract
The invention provides, in various embodiments, devices and methods relating to ex-vivo organ care. In certain embodiments, the invention relates to aortic cannulas for use in perfusion systems to return perfusate to the heart or delivering perfusate from the heart while the organ is sustained ex vivo at physiologic or near-physiologic conditions.
Description
TECHNICAL FIELD

The present invention relates generally to medical devices and, in particular, aortic cannulas for use in ex vivo organ care systems. Specifically the invention relates to aortic cannulas used to return perfusate to the heart or delivering perfusate from the heart while the organ is sustained ex vivo at physiologic or near-physiologic conditions.


BACKGROUND

Current organ preservation techniques typically involve hypothermic storage of the organ in a chemical perfusate solution on ice. However, uses of conventional approaches results in injuries that increase as a function of the length of time an organ is maintained ex-vivo. These time restrictions limit the number of recipients who can be reached from a given donor site, thereby restricting the recipient pool for a harvested heart. Even within the few hour time limit, the heart may nevertheless be significantly damaged.


Effective preservation of an ex-vivo organ would also provide numerous other benefits. For instance, prolonged ex-vivo preservation would permit more careful monitoring and functional testing of the harvested organ. This would in turn allow earlier detection and potential repair of defects in the harvested organ, further reducing the likelihood of transplantation failure. The ability to perform simple repairs on the organ would also allow many organs with minor defects to be saved, whereas current transplantation techniques require them to be discarded. In addition, more effective matching between the organ and a particular recipient may be achieved, further reducing the likelihood of eventual organ rejection.


Improved ex-vivo organ care has been achieved through the use of an ex-vivo organ care system which maintains organs at physiologic or near-physiologic conditions. Not only does the system maintain the organ at physiologic temperatures, but in the case of the heart, the system maintains perfusate flow through the organ. In addition the system measures and monitors electric stimulation in the heart. The ex vivo organ care system where the heart sustained ex vivo at physiologic or near-physiologic conditions are described in application Ser. No. 11/822,495 entitled “Systems for monitoring and applying electrical currents in an organ perfusion system,” U.S. Pat. No. 8,304,181 entitled “Method for ex-vivo organ care and for using lactate as an indication of donor organ status,” and U.S. Pat. No. 8,409,846 entitled “Compositions, methods and devices for maintaining an organ,” which are incorporated herein by reference.


To maintain physiologic or near-physiologic perfusate flow through the heart, the organ must interface with the system via the aorta. This interface is achieved via an aortic cannula. Current aortic cannula designs lead to organ slippage, difficulties in maintaining a liquid tight seal, and damage to the aorta. Often these designs rely solely upon a cable tie in contact with the aorta to tighten the aorta to the aortic cannula. Depending on the size of the aorta and the size of the aortic cannula, there is a risk of laceration due to the cable ties exerting too much tension on aortic tissue, or the risk of leakage if they do not exert sufficient tension. Thus, there exists a need for an aortic cannula that is easy for health care workers to deploy, creates a tight seal with the aorta, reduces aortic slipping, and causes minimal damage to the aorta.


In view of the foregoing, improved devices for attaching the aorta to the system and methods of use in ex vivo organ care systems are needed.


SUMMARY

In one embodiment the invention includes an aortic cannula for use with an ex vivo organ care system and methods of using the same. One aspect of the invention includes an aortic cannula comprising, a cannula body which further comprises, a fitting adapted to connect to an organ care system, an aorta interface to contact an aorta, and a pivot arm strap operably connected to a pivot mount, wherein the pivot mount allows the pivot arm strap to uniformly contact the aorta to hold the aorta on the aorta interface. In one embodiment, the aortic cannula further comprises a pivot arm connected to the pivot arm strap and to the pivot mount, such that when the pivot arm is moved toward the cannula body by rotation around the pivot mount the pivot arm strap moves away from the cannula body. In another embodiment of the aortic cannula the pivot arm and the pivot arm strap are parts of a single piece. In another embodiment, the aortic cannula comprises a spring which applies pressure to the pivot arm strap to hold the aorta on the aorta interface. In another embodiment of the aortic cannula a dowel pin communicates with the spring to allow the pivot arm to rotate around the dowel pin. In another embodiment of the aortic cannula the pivot arm further comprises a grip pad used to depress the top of the pivot arm. In another embodiment of the aortic cannula the grip pad is textured. In another embodiment of the aortic cannula the grip pad is removable. In another embodiment of the aortic cannula the pivot arm straps further comprise a loop and guide which retain a cable tie around the pivot arm strap. In another embodiment, the aortic cannula further comprises windows sized to normalize the compression exerted on the aorta by the cable tie such that the same amount of pressure will be exerted on the aorta regardless of the size of the pivot arm strap for a given cable tie tension. In another embodiment, the aortic cannula further comprises a connector used to reversibly secure the aortic cannula to an organ chamber. In another embodiment of the aortic cannula the connector is a threaded locking nut. In another embodiment of the aortic cannula the aorta interface is textured.


One aspect of the invention includes a method of using an aortic cannula to place a heart in fluid communication with an organ care system the method comprising, selecting an aortic cannula sized to fit the aorta of the heart the aortic cannula comprising, a cannula body further comprising, a fitting adapted to connect to an organ care system, an aorta interface to contact an aorta, and a pivot arm strap operably connected to a pivot mount, wherein the pivot mount allows the pivot arm strap to uniformly contact the aorta to hold the aorta on the aorta interface, depressing the pivot arm such that it rotates around the dowel pin and the pivot arm strap moves away from the cannula body, placing the cannula in the aorta, releasing the pivot arm, tightening a cable tie around the pivot arm strap to hold the aorta in place, and inserting the tapered fitting into an organ care system. In one embodiment, the method further comprises the step of suturing surgical felt pledgets on the aorta before placing the aorta on the aortic cannula.





BRIEF DESCRIPTION OF THE FIGURES

The following figures depict illustrative embodiments of the invention.



FIG. 1 illustrates a diagram depicting an aortic cannula in one embodiment.



FIG. 2a illustrates a side view of a cannula body in one embodiment.



FIG. 2b illustrates a side view of a cannula body and a spring pocket according to one embodiment.



FIG. 2c illustrates a side view of a cannula body in one embodiment.



FIG. 3a illustrates one embodiment of a pivot arm.



FIG. 3b illustrates a side view of a pivot arm and strap according to one embodiment.



FIG. 3c illustrates another view of a pivot arm and strap according to one embodiment.



FIG. 3d illustrates another view of a pivot arm and strap according to one embodiment.



FIG. 3e illustrates a top view of a pivot arm and strap according to one embodiment.



FIG. 4 illustrates a diagram showing the shape of a cannula body texture in one embodiment.



FIG. 5 illustrates a top view of a pivot mount according to one embodiment.



FIG. 6 illustrates a tip holder according to one embodiment.





DETAILED DESCRIPTION

Cannula Body



FIG. 1 is a diagram depicting the aortic cannula 100 in one embodiment. The aortic cannula device 100 comprises a cannula body 114, a locking nut 102, and a pivot arm 140. The cannula body 114 may contain three sub-sections, a tapered fitting 108, a tapered midsection 130 and an aorta interface 132. These subsections can be seen in FIG. 1 as well as in various side views of the cannula body 114 depicted in FIGS. 2a-2b. In one embodiment, the cannula body 114 is made from injection molded clear polycarbonate. However, one of skill in the art would understand that the cannula body can be made from other types of plastic or any other suitable material.


One of skill in the art would recognize that the while the shape of the cannula body 114 should be generally cylindrical, the opening need not be perfectly circular. The three sub-sections, tapered fitting 108, tapered midsection 130, and aorta interface 132, may be of different lengths relative to one another. In addition the different subsections may be made from one piece and they may have the same diameter. One of skill in the art would also recognize that the taper angle in the sub-sections, tapered fitting 108, tapered midsection 130, and aorta interface 132, may vary so long as the aorta interface reaches a diameter within the typical range of the diameter of an human aorta.


One end of the aortic cannula 100 forms tapered fitting 108. The tapered fitting is sized to couple to a female connector on an organ chamber (not shown) to create a seal. A threaded locking nut 102, pictured in FIG. 1, is used to reversibly secure the aortic cannula 100 to the organ chamber (not shown). In one embodiment, the locking nut 102 has four wings 104 extending from its outer surface that are used for gripping and turning the locking nut 102. In one embodiment the wings 104 are rectangular. One of skill in the art would understand that the wings 104 could be any shape or omitted. The locking nut 102 may have a lip protruding inward from its bottom edge that snaps over locking ridge 110 and into the locking groove 112 on the cannula body 114. The locking groove 112 and the locking ridge 110 can be seen in FIG. 1 and FIGS. 2a-2b. Alternatively, the locking nut 102 may be secured to the cannula body 114 using other mechanisms known to one skilled in the art. Once the locking nut 102 is seated in the locking groove 112, the aortic cannula 100 is securely fastened to the organ chamber (not shown) by turning the locking nut 102. Perfusate can be perfused through the cannula into the heart without leaking. One of skill in the art would understand that other designs can be used to attach the aortic cannula 100 to the organ chamber to prevent leakage.


One of skill in the art would understand that the aortic cannula 100 can be connected to an organ care system or any other tube, device, or path of flow. In addition, one of skill in the art would appreciate that the locking nut 102 may be omitted in embodiments where the male-female connection between the aortic cannula 100 and the organ care system (not shown) is tight enough to prevent leakage. One of skill in the art would also recognize that the locking nut 102 could be replaced with other types of connectors generally used in the art to create a flow path between two tubes.


The tapered midsection 130 extends from the bottom edge of the tapered fitting 108 to the top edge of the aorta interface 132. The tapered midsection 130 reaches a final diameter the size of the aorta interface 132. The tapered midsection 130 helps to ensure smooth fluid flow from the aorta interface 132 to the tapered fitting 108. The tapered midsection 130 also helps minimize air trap and hemolysis and improve hemodynamics due to the smooth transition in flow path. The tapered midsection 130 has a pivot mount 122 and a spring pocket 106. The pivot mount 122 and the spring pocket 106 may be integrated with the tapered midsection 130. In one embodiment, the tapered midsection 130 has two pivot mounts 122 and two spring pockets 106, shown in FIGS. 1 and 2b. The pivot mounts 122 are located on each side of the cannula body 114. One of ordinary skill in the art would understand that one or more pivot mounts 122 and spring pockets 106 could be used. As shown in FIG. 5, in one embodiment the pivot mount 122 has a circular center hole 138 sized to receive a dowel pin 120. The spring pocket 106 is located on the cannula body 114 and provides a space for a torsional spring (not shown). The dowel pin 120 fits through one side of the center hole 138 on the integrated pivot mount 122, through the center of the torsional spring in the spring pocket 106, and through the other side of the center hole 138 on the integrated pivot mount 122. The torsional spring is oriented in spring pocket 106 such that depressing the pivot arm compresses the spring. One end of the torsional spring rests in the spring end pocket 134 on the thumb pad 116 seen in FIG. 3a. One of ordinary skill in the art would understand that there are various ways to attach the pivot mount 122 to the cannula body 114 that allows the pivot mount 122 to pivot or move so that the aorta can be fit onto the cannula body 114 in operation. In one embodiment, the pivot mount 122 is made from injection molded polycarbonate, acetyl, or any suitable material.


One of skill in the art would also recognize that the torsional spring could be replaced with other types of spring loading mechanisms or omitted completely. The torsional spring could also be replaced by a molded leaf spring on the pivot arm or on the grip pad. With the use of a molded leaf spring the dowel pin would be omitted and cylindrical bosses on the cannula body 114 or a similar structure could be used to perform the same function.


The aorta interface 132 is located adjacent the tapered midsection 130. The aorta interface 132 may be of a constant diameter and sized to fit within the aorta. The diameter of the aorta interface 132 can be between 0.5 and 2 inches. In some embodiments the diameter of the aorta interface 132 can be between 0.75 and 1.125 inches. Preferably, in some embodiments the diameter of the aorta interface is 0.75 inches, 0.875 inches, 1 inch, or 1.125 inches. The aorta interface 132 may be smooth or textured. FIG. 1 illustrates a texture 128 on the aorta interface 132 to help prevent the aorta from slipping off of the cannula body 114. In the embodiment shown in FIG. 1, the aortic cannula 100 is placed in the aorta so that the aorta does not rise above the end of the texture 128. FIG. 4 is a cross sectional view of one embodiment of the texture 128. The texture 128 may be of any shape. In one embodiment the texture 128 comprises concentric ridges extending around the aorta interface 132 that are sloped at a 45 degree angle on their lower side and are perpendicular to the cannula body 114 on their upper face. This design allows the aorta to slide onto the aorta interface 132 easily, but prevents the aorta from sliding off the aorta interface 132. Preferably the ridges are about 0.005 inches tall. However, one of skill in the art would understand that the texture features could be of any shape and size to allow the aorta to be situated around the aorta interface 132 and to help hold the aorta in place while minimizing damage to the tissue. In one embodiment, the radial edge of the aortic interface 132 does not have a ridge to minimize trauma to the tissue. Alternatively, one of skill in the art would recognize that a ridge could be designed to minimize tissue trauma and to hold the aorta in place.


Pivot Arm


A pivot arm 140 is coupled to the pivot mount 122. FIGS. 3a-e illustrate different views of a pivot arm and pivot arm strap (discussed below) in one embodiment. The pivot arm 140 allows the device 100 to adjust and grip aortas of different thicknesses. In one embodiment the cannula body 114 includes two pivot arms 140 coupled to two pivot mounts 122 on the cannula body. One of ordinary skill would understand that the number of pivot arms 140 corresponds to the number of pivot mounts 122. The pivot arm 140 comprises a grip pad 116, a sliding pivot window 118, and a strap 124. The sliding pivot window 118 allows the strap 124 to maintain uniform contact with the aorta through a range of motion. The grip pad 116 can be smooth, or contain features such as molded ridges or other texture to stop the user's fingers from slipping. The grip pad can be any shape, preferably round. In some embodiments the grip pad 116 may be detachable. In other embodiments a reusable tool that attaches to the pivot arms 140 could be used in place of the grip pads 116. The dowel pin 120 allows the pivot arm 140 to rotate around the dowel pin 120 when it is actuated. The pivot arm 140 is made from injection molded acetyl or any material with similar properties. One of skill in the art would recognize that while the sliding pivot provides certain advantages over a fixed pivot point, a fixed pivot point could also be used. Some embodiments may include a locking mechanism to hold the pivot arm 140 in an open position.


Pivot Arm Strap


The pivot arm strap 124 is coupled to the pivot arm 140. The pivot arm strap is best seen in FIGS. 1 and 3. As shown in FIG. 1, in one embodiment the cannula body 114 includes two pivot arm straps 124 coupled to two pivot arms 140. One of ordinary skill would understand that the number of pivot straps 124 corresponds to the number of pivot arms 140. The pivot arm strap 124 and the sliding pivot window 118 allow the cannula body 114 to uniformly grip the aorta. The pivot arm strap 124 is designed to be stiff enough to hold the aorta, while maintaining enough flexibility to conform to the aorta and minimize tissue damage. The pivot arm straps 124 are curved. The pivot arm strap 124 optionally has a loop 136 and a guide 142 to retain a cable tie (not shown) around the pivot arm strap 124. The cable tie is made from a flexible nylon material or material with similar properties. Once the cable tie has been threaded through the loop 136 and slotted in the guide 142, it is tightened to the desired tension. The amount that the cable tie is tightened is the same for all sizes of cannulas. Windows 126 in the pivot arm strap 124 normalize the pressure exerted on the aorta by altering the surface area of the strap in contact with the aorta. Accordingly, the size of the windows 126 vary depending on the size of the aorta. The size of the windows 126 are calculated so that when the cable tie is tightened, it exerts the same compression on the aorta for every size device 100. Thus, the compression exerted on the aorta holds it in place without damaging the tissue. One of ordinary skill would understand that alternatively, the cable tie may be tightened to a specific tension for each size of the device 100. In addition, other mechanisms of clamping to hold the aorta in place could be used in place of the cable tie, for example a hose clamp or a tension strap. Additionally, the pivot arm strap 124 and the windows 126 could be of different shapes and sizes. Alternatively, the windows could be omitted. One of skill in the art would also understand that the pivot arm 140 and the pivot arm strap 124 could be sections of a single piece. In addition, one of skill in the art would understand that the inner surface of the pivot arm strap 124 could be smooth, or textured for additional traction.


In one embodiment, the aorta is secured to the cannula body. The grip pad 116 is depressed by the user causing the pivot arm 140 to move around the sliding pivot window 118 and to compress torsional spring. The pivot arm 140 rotates around the dowel pin 120 in the sliding pivot window 118 and the pivot arm straps 124 move away from the cannula body 114, which makes room to place the cannula in the aorta in a preferred manner than if the pivot point were fixed. When the grip pad 116 is released the torsional spring (not shown) exerts pressure on the pivot arm strap 124 and temporarily holds the aorta in place. The straps closes on the aorta and the sliding pivot window 118 allows the pivot point to change in order to compensate for variations in tissue thickness and maintain alignment and concentricity of pivot arm 140 to cannula body 114 through the full range of rotation. This allows the strap 124 to seat uniformly on the aorta. Then, the cable tie is threaded through the loop 136 and between the guide 142. The cable tie is tightened to a predetermined tension. One of skill in the art would understand that the cable tie could be replaced with other mechanisms for securing the pivot arm straps 124. In some embodiments the cable tie can come preassembled in the loops 136.


Pledgets


In some embodiments, the user may suture surgical felt pledgets on the aorta. The pledgets serve as an additional measure to retain the aorta on the cannula body 114 because the pledgets provide a barrier that does not slide between the pivot arm strap 124 and the cannula body 114. Four sets of two (one inside, one outside) pledgets are equally spaced around the aorta and sutured. One of skill in the art will recognize that more or fewer pledgets may be used. In one embodiment, the aorta is positioned onto the cannula body 114 so that the pledgets are not directly above a space between the pivot arms 140 to prevent the pledgets from sliding through the space between the two sides of the pivot arm straps 124. It will be recognized by one of skill in the art that the pledgets may be placed anywhere on the aorta and end up in any orientation with respect to the pivot arm straps. The pledgets may be standard, surgical felt pledgets. Alternatively, they may be injected molded, rigid, elastomeric pledgets made of a high Durometer material, such as silicone, or a similar material. One of skill in the art would understand that the pledgets could be replaced with other materials that attach to the tissue, and that provide an anchor to prevent the device from sliding between the strap and the cannula body or damaging the tissue. Examples of these materials include, but are not limited to, a continuous ring of material that attaches to the tissue or a staple.


Tip Holder



FIG. 6 depicts a tip holder 601. The tip holder 601 is generally cylindrical, though it may have other shapes. The tip holder has a handle 603. The handle may take any shape that allows a user to hold the tip holder 601. The tip holder 601 can also have threads 602. The locking nut 102 can be screwed onto the threads 602. The tip holder 601 can also have a stopper 604 which protrudes from the tip holder 601 and serves as a stopping point for the locking nut 102. One of skill in the art would understand that other designs can be used to attach the locking nut to the tip holder. Alternatively, the tip holder may be secured to the aortic cannula 100 using other mechanisms known to one skilled in the art. Once secured, the tip holder can be used to hold the aortic cannula 100 with or without a heart positioned on the aortic cannula 100.


Example 1

The aortic cannula 100 may be used to connect a heart to an organ chamber (not shown). The aortic cannula 100 holds the aorta open and in place and allows perfusate to be perfused through the heart so the heart can be maintained in near physiologic conditions. In one embodiment, to deploy the aortic cannula, the user first selects an aortic cannula 100 that is sized to fit the heart. In one embodiment the aortic cannula 100 may be selected by measuring the aorta. The user depresses the thumb pads 116 on the spring-loaded pivot arms. When the user depresses the grip pads 116, the pivot arms 140 rotate around the dowel pin 120 within the sliding pivot window 118 and the pivot arm straps 124 move away from the cannula body 114 making room to place the cannula in the aorta. The user can place the cannula in the aorta. Then the user releases the thumb pads allowing the pivot arms 140 to close on the aorta. The pivot arms 140 may be operated at the same time or individually. The pressure created by the torsional springs temporarily holds the aorta in place. The user may adjust the aorta position, if necessary, such that aorta is fully engaged on the cannula body 114. Next the user places a cable tie through the loops 136 and guides 142 in the pivot arm straps 124. The user then tightens the cable tie to hold the aorta in place. In some embodiments the cable tie may be tightened using a tool which tightens the cable tie to a predetermined force. The user inserts the tapered fitting 108 into the organ chamber (not shown). Then the user tightens the locking nut 102. One of skill in the art will recognize that in some embodiments the aortic cannula 100 could first be seated in the organ chamber and then the aorta could be secured to the aortic cannula 100.

Claims
  • 1. An aortic cannula for use in an ex vivo organ care system comprising: a cannula body comprising: a fitting adapted to connect to an organ care system;an aorta interface to contact an aorta; andtwo or more pivot mounts; andtwo or more pivot arm straps operably connected to the two or more pivot mounts, the two or more pivot arm straps being shaped to uniformly contact the aorta when the aorta is arranged on the aorta interface, whereinthe two or more pivot mounts are configured to allow the two or more pivot arm straps to move into contact with the aorta to hold the aorta on the aorta interface.
  • 2. The aortic cannula of claim 1, further comprising a pivot arm connected to a first pivot arm strap of the two or more pivot arm straps and connected to a first pivot mount of the two or more pivot mounts, whereinmoving a grip pad of the pivot arm toward the cannula body causes the first pivot arm strap to move away from the cannula body.
  • 3. The aortic cannula of claim 2, wherein the pivot arm and the first pivot arm strap form a single, plastic member.
  • 4. The aortic cannula of claim 1, further comprising a spring operably coupled to apply force to the first pivot arm strap to hold the aorta on the aorta interface.
  • 5. The aortic cannula of claim 4, wherein a dowel pin communicates with the first pivot mount and communicates with the pivot arm to allow the pivot arm to rotate with respect to the first pivot mount.
  • 6. The aortic cannula of claim 2, wherein the grip pad of the pivot arm is a thumb pad used to depress a top surface of the pivot arm.
  • 7. The aortic cannula of claim 6, wherein the thumb pad is textured with a non-smooth texture.
  • 8. The aortic cannula of claim 2, wherein at least one pivot arm strap of the two or more pivot arm straps further comprise a loop and a guide configured to retain a cable tie around the at least one pivot arm strap.
  • 9. The aortic cannula of claim 8, wherein the at least one pivot arm strap of the two or more pivot arm straps has a window sized to normalize a compression exerted on the aorta by the cable tie such that a same amount of pressure is exerted on the aorta regardless of a size of the at least one pivot arm strap for a given cable tie tension.
  • 10. The aortic cannula of claim 1, further comprising a connector used to reversibly secure the aortic cannula to an organ chamber.
  • 11. The aortic cannula of claim 10, wherein the connector is a threaded locking nut.
  • 12. The aortic cannula of claim 1, wherein the aorta interface is textured with a non-smooth texture.
  • 13. An aortic cannula for use in an ex vivo organ care system, the aortic cannula comprising: a cannula body, comprising: a fitting shaped to connect to an organ chamber assembly;an aorta interface configured to fit within an aorta; anda pivot mount;a pivot arm operably connected to the pivot mount, the pivot arm comprising: a pivot arm strap configured to hold the aorta against the aorta interface, anda sliding pivot window configured to allow the pivot arm strap to maintain contact with the aorta through a range of motion; anda dowel pin operably connected to the pivot mount and arranged in the sliding pivot window of the pivot arm, wherein the pivot arm is configured to rotate around the dowel pin, and the pivot arm is configured for the dowel pin to be translated along a length of the sliding pivot window.
  • 14. The aortic cannula of claim 13, wherein the cannula body further comprises a tapered midsection extending from the fitting to the aorta interface, andthe pivot arm further comprises a grip pad that can be used to depress a top of the pivot arm.
  • 15. The aortic cannula of claim 14, further comprising a locking nut configured to reversibly secure the aortic cannula to the organ chamber assembly.
  • 16. The aortic cannula of claim 14, further comprising a spring operably coupled to apply a force between the pivot arm and the cannula body, wherein the force directs the pivot arm strap toward the aorta interface to fix an aorta in a position when the aorta is arranged on the aorta interface.
  • 17. The aortic cannula of claim 14, wherein the pivot arm strap further comprises a loop and a guide configured to retain a cable tie around the pivot arm strap.
  • 18. The aortic cannula of claim 17, further comprising a window sized to normalize the compression exerted on the aorta by the cable tie such that about a same amount of pressure is exerted on the aorta regardless of a size of the pivot arm strap for a given cable tie tension.
RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/258,194 filed Sep. 7, 2016 which claims the benefit of U.S. Provisional Application Ser. No. 62/215,825, titled “Aortic Cannula for Ex Vivo Organ Care System,” filed Sep. 9, 2015. The specifications of each of the foregoing are incorporated by reference herein in their entirety.

US Referenced Citations (251)
Number Name Date Kind
3253595 Keller, Jr. et al. May 1966 A
3388803 Scott Jun 1968 A
3406531 Koski et al. Oct 1968 A
3468136 Koski et al. Sep 1969 A
3537956 Falcone Nov 1970 A
3545221 Koski et al. Dec 1970 A
3545605 Robins Dec 1970 A
3587567 Schiff Jun 1971 A
3607646 de Roissart Sep 1971 A
3632473 Belzer et al. Jan 1972 A
3639084 Goldhaber Feb 1972 A
3654085 Fritz et al. Apr 1972 A
3660241 Michielsen May 1972 A
3738914 Thorne et al. Jun 1973 A
3772153 De Roissart Nov 1973 A
3777507 Burton et al. Dec 1973 A
3843455 Bier et al. Oct 1974 A
3851646 Sarns Dec 1974 A
3881990 Burton et al. May 1975 A
3995444 Clark et al. Dec 1976 A
4186565 Toledo-Pereyra Feb 1980 A
4231354 Kurtz et al. Nov 1980 A
4415556 Bretschneider Nov 1983 A
4598697 Numazawa et al. Jul 1986 A
4605644 Foker Aug 1986 A
4666425 Fleming May 1987 A
4719201 Foker Jan 1988 A
4723939 Anaise Feb 1988 A
4745759 Bauer et al. May 1988 A
4759371 Franetzki Jul 1988 A
4801299 Brendel et al. Jan 1989 A
4847470 Bakke Jul 1989 A
4920044 Bretan, Jr. Apr 1990 A
5051352 Martindale et al. Sep 1991 A
5066578 Wikman-Coffelt Nov 1991 A
5141847 Sugimachi et al. Aug 1992 A
5145771 Lemasters et al. Sep 1992 A
5157930 McGhee et al. Oct 1992 A
5200398 Strasberg et al. Apr 1993 A
5217860 Fahy et al. Jun 1993 A
5285657 Bacchi et al. Feb 1994 A
5306711 Andrews Apr 1994 A
5326706 Yland et al. Jul 1994 A
5338662 Sadri Aug 1994 A
5356593 Heiberger et al. Oct 1994 A
5356771 O'Dell Oct 1994 A
5358931 Rubinsky et al. Oct 1994 A
5362622 O'Dell et al. Nov 1994 A
5370989 Stern et al. Dec 1994 A
5381510 Ford et al. Jan 1995 A
5385821 O'Dell et al. Jan 1995 A
5395314 Klatz et al. Mar 1995 A
5405742 Taylor Apr 1995 A
5407669 Lindstrom et al. Apr 1995 A
5407793 Del Nido et al. Apr 1995 A
5472876 Fahy Dec 1995 A
5473791 Holcomb et al. Dec 1995 A
5494822 Sadri Feb 1996 A
5498427 Menasche Mar 1996 A
5505709 Funderburk et al. Apr 1996 A
5514536 Taylor May 1996 A
5552267 Stern et al. Sep 1996 A
5554123 Herskowitz Sep 1996 A
5554497 Raymond Sep 1996 A
5571801 Segall et al. Nov 1996 A
5584804 Klatz et al. Dec 1996 A
5586438 Fahy Dec 1996 A
5588816 Abbott et al. Dec 1996 A
5599173 Chen et al. Feb 1997 A
5599659 Brasile et al. Feb 1997 A
5613944 Segall et al. Mar 1997 A
5643712 Brasile Jul 1997 A
5654266 Chen et al. Aug 1997 A
5656420 Chien Aug 1997 A
5679565 Mullen et al. Oct 1997 A
5693462 Raymond Dec 1997 A
5698536 Segall et al. Dec 1997 A
5699793 Brasile Dec 1997 A
5702881 Brasile et al. Dec 1997 A
5716378 Minten Feb 1998 A
5723281 Segall et al. Mar 1998 A
5733894 Segall et al. Mar 1998 A
5747071 Segall et al. May 1998 A
5752929 Klatz et al. May 1998 A
5770149 Raible Jun 1998 A
5776063 Dittrich et al. Jul 1998 A
5786136 Mayer Jul 1998 A
5787544 Meade Aug 1998 A
5807737 Schill et al. Sep 1998 A
5823799 Tor et al. Oct 1998 A
5843024 Brasile Dec 1998 A
5856081 Fahy Jan 1999 A
5882328 Levy et al. Mar 1999 A
5965433 Gardetto et al. Oct 1999 A
5998240 Hamilton et al. Dec 1999 A
6024698 Brasile Feb 2000 A
6034109 Ramasamy et al. Mar 2000 A
6042550 Haryadi et al. Mar 2000 A
6046046 Hassanein Apr 2000 A
6050987 Rosenbaum Apr 2000 A
6100082 Hassanein Aug 2000 A
6110139 Loubser Aug 2000 A
6110504 Segall et al. Aug 2000 A
6144444 Haworth et al. Nov 2000 A
6168877 Pedicini et al. Jan 2001 B1
6365338 Bull et al. Apr 2002 B1
6375611 Voss et al. Apr 2002 B1
6375613 Brasile Apr 2002 B1
6389308 Shusterman May 2002 B1
6402461 Tebby Jun 2002 B1
6475716 Seki Nov 2002 B1
6490880 Walsh Dec 2002 B1
6492103 Taylor Dec 2002 B1
6492745 Colley, III et al. Dec 2002 B1
6524785 Cozzone et al. Feb 2003 B1
6569615 Thatte et al. May 2003 B1
6582953 Brasile Jun 2003 B2
6600941 Khuri Jul 2003 B1
6609987 Beardmore Aug 2003 B1
6631830 Ma et al. Oct 2003 B2
6642045 Brasile Nov 2003 B1
6673594 Owen et al. Jan 2004 B1
6696238 Murphy et al. Feb 2004 B2
6740484 Khirabadi et al. May 2004 B1
6783328 Lucke et al. Aug 2004 B2
6792309 Noren Sep 2004 B1
6794124 Steen Sep 2004 B2
6811965 Vodovotz et al. Nov 2004 B2
6878339 Akiyama et al. Apr 2005 B2
6894690 Capers May 2005 B2
6906325 Quek Jun 2005 B2
6925324 Shusterman Aug 2005 B2
6953655 Hassanein et al. Oct 2005 B1
6974436 Aboul-Hosn et al. Dec 2005 B1
7001354 Suzuki et al. Feb 2006 B2
7008380 Rees et al. Mar 2006 B1
7238165 Vincent et al. Jul 2007 B2
7316666 Entenman et al. Jan 2008 B1
7452711 Daykin Nov 2008 B2
7572622 Hassanein et al. Aug 2009 B2
7651835 Hassanein et al. Jan 2010 B2
8304181 Hassanein et al. Nov 2012 B2
8323954 Kravitz et al. Dec 2012 B2
8409846 Hassanein et al. Apr 2013 B2
8420380 Fishman et al. Apr 2013 B2
8465970 Hassanein et al. Jun 2013 B2
8535934 Hassanein et al. Sep 2013 B2
8585380 Hassanein et al. Nov 2013 B2
8822203 Hassanein et al. Sep 2014 B2
9215867 Hassanein et al. Dec 2015 B2
9457179 Hassanein et al. Oct 2016 B2
9462802 Fishman et al. Oct 2016 B2
9894894 Hassanein et al. Feb 2018 B2
10321676 Hassanein et al. Jun 2019 B2
10736314 Hassanein et al. Aug 2020 B2
10750738 Fishman et al. Aug 2020 B2
20010003652 Freeman Jun 2001 A1
20010025191 Montgomery Sep 2001 A1
20020012988 Brasile Jan 2002 A1
20020102720 Steen Aug 2002 A1
20020132220 Berens et al. Sep 2002 A1
20020151950 Okuzumi Oct 2002 A1
20020164795 Gen Nov 2002 A1
20020177117 Wolf Nov 2002 A1
20020187132 Mcgregor et al. Dec 2002 A1
20030040665 Khuri et al. Feb 2003 A1
20030050689 Matson Mar 2003 A1
20030053998 Daemen et al. Mar 2003 A1
20030073227 Hull et al. Apr 2003 A1
20030074760 Keller Apr 2003 A1
20030086830 Haywood et al. May 2003 A1
20030111604 Quek Jun 2003 A1
20030135152 Kollar et al. Jul 2003 A1
20030147466 Liang Aug 2003 A1
20040015042 Vincent et al. Jan 2004 A1
20040017658 Lo et al. Jan 2004 A1
20040018966 Segall et al. Jan 2004 A1
20040029096 Steen Feb 2004 A1
20040038192 Brasile Feb 2004 A1
20040058432 Owen et al. Mar 2004 A1
20040082057 Alford et al. Apr 2004 A1
20040086578 Segall et al. May 2004 A1
20040102415 Thatte et al. May 2004 A1
20040102678 Haindl May 2004 A1
20040106958 Mathis et al. Jun 2004 A1
20040110800 Bril et al. Jun 2004 A1
20040115689 Augello et al. Jun 2004 A1
20040138542 Khuri et al. Jul 2004 A1
20040168341 Petersen et al. Sep 2004 A1
20040170950 Prien Sep 2004 A1
20040171138 Hassanein et al. Sep 2004 A1
20040193096 Cooper Sep 2004 A1
20040202993 Poo et al. Oct 2004 A1
20040221719 Wright et al. Nov 2004 A1
20040224298 Brassil et al. Nov 2004 A1
20040235142 Schein et al. Nov 2004 A1
20040236170 Kim Nov 2004 A1
20040248281 Wright et al. Dec 2004 A1
20050010118 Toyoda et al. Jan 2005 A1
20050019917 Toledo-Pereyra et al. Jan 2005 A1
20050142532 Poo et al. Jun 2005 A1
20050147958 Hassanein et al. Jul 2005 A1
20050153271 Wenrich Jul 2005 A1
20050170019 Roth Aug 2005 A1
20050182349 Linde et al. Aug 2005 A1
20050187469 Phillips Aug 2005 A1
20050253390 Blazek Nov 2005 A1
20060039870 Turner Feb 2006 A1
20060074470 Bartels et al. Apr 2006 A1
20060121438 Toledo-Pereyra et al. Jun 2006 A1
20060124130 Bonassa Jun 2006 A1
20060134073 Naka et al. Jun 2006 A1
20060148062 Hassanein et al. Jul 2006 A1
20060154357 Hassanein et al. Jul 2006 A1
20060154359 Hassanein et al. Jul 2006 A1
20060160204 Hassanein et al. Jul 2006 A1
20060292544 Hassanein et al. Dec 2006 A1
20070196461 Weers Aug 2007 A1
20070275364 Hassanein et al. Nov 2007 A1
20080017191 Davies et al. Jan 2008 A1
20080017194 Hassanein et al. Jan 2008 A1
20080234768 Hassanein et al. Sep 2008 A1
20080286746 Poo et al. Nov 2008 A1
20090142830 Yamashiro et al. Jun 2009 A1
20090143417 Smith et al. Jun 2009 A1
20090197240 Fishman et al. Aug 2009 A1
20090197241 Fishman et al. Aug 2009 A1
20090197292 Fishman et al. Aug 2009 A1
20090197324 Fishman et al. Aug 2009 A1
20090197325 Fishman et al. Aug 2009 A1
20090215022 Page et al. Aug 2009 A1
20090312724 Pipkin et al. Dec 2009 A1
20100056966 Toth Mar 2010 A1
20100092939 Belous et al. Apr 2010 A1
20100119554 Dobson May 2010 A1
20110076666 Brassil Mar 2011 A1
20110136096 Hassanein et al. Jun 2011 A1
20110190572 Brophy et al. Aug 2011 A1
20110212431 Bunegin et al. Sep 2011 A1
20120277681 Kravitz Nov 2012 A1
20130011823 Hassanein et al. Jan 2013 A1
20130078710 Hassanein et al. Mar 2013 A1
20130157248 Fishman et al. Jun 2013 A1
20130295552 Hassanein et al. Nov 2013 A1
20140017658 Steinman et al. Jan 2014 A1
20140017660 Steinman et al. Jan 2014 A1
20140135738 Panian May 2014 A1
20150079580 Hassanein et al. Mar 2015 A1
20150230453 Fontes et al. Aug 2015 A1
20200337298 Hassanein et al. Oct 2020 A1
20200352155 Fishman et al. Nov 2020 A1
Foreign Referenced Citations (81)
Number Date Country
2881613 Nov 2007 CA
1232723 Oct 1999 CN
1269471 Oct 2000 CN
2418882 Feb 2001 CN
1452863 Nov 2003 CN
101072500 Nov 2007 CN
101404968 Apr 2009 CN
101977649 Feb 2011 CN
4201259 Jul 1993 DE
10121159 Nov 2002 DE
0347923 Dec 1989 EP
0376763 Jul 1990 EP
1017271 Jul 2000 EP
1942726 Jul 2008 EP
3347084 Nov 2020 EP
S57-010695 Jan 1982 JP
63270601 Nov 1988 JP
H02-282301 Nov 1990 JP
02-306901 Dec 1990 JP
H03-74302 Mar 1991 JP
04-099701 Mar 1992 JP
H04-128201 Apr 1992 JP
06-056601 Mar 1994 JP
06-305901 Nov 1994 JP
H07-196401 Aug 1995 JP
08-511012 Nov 1996 JP
09-500380 Jan 1997 JP
H09-500481 Jan 1997 JP
2001061956 Mar 2001 JP
2001516768 Oct 2001 JP
2002-119586 Apr 2002 JP
2003-206201 Jul 2003 JP
2003-315220 Nov 2003 JP
2004513889 May 2004 JP
2004525290 Aug 2004 JP
2004529938 Sep 2004 JP
2008-515914 May 2008 JP
2009-521931 Jun 2009 JP
2010-525076 Jul 2010 JP
2011-511000 Apr 2011 JP
2016-53030 Apr 2016 JP
6144238 Jun 2017 JP
6625384 Dec 2019 JP
2020-138976 Sep 2020 JP
6756775 Sep 2020 JP
6757829 Sep 2020 JP
WO-8805261 Jul 1988 WO
WO-9502326 Jan 1995 WO
WO-9503680 Feb 1995 WO
WO-9531897 Nov 1995 WO
WO-9618293 Jun 1996 WO
WO-9629865 Oct 1996 WO
WO-9746091 Dec 1997 WO
WO-9915011 Apr 1999 WO
WO-0022927 Apr 2000 WO
WO-0035340 Jun 2000 WO
WO-0060936 Oct 2000 WO
WO-0226034 Apr 2002 WO
WO-0235929 May 2002 WO
WO-02089571 Nov 2002 WO
WO-2003026419 Apr 2003 WO
WO-2004017838 Mar 2004 WO
WO-2004026031 Apr 2004 WO
WO-2006042138 Apr 2006 WO
WO-2006060309 Jun 2006 WO
WO-2006076590 Jul 2006 WO
WO-2006124820 Nov 2006 WO
WO-2007079185 Jul 2007 WO
WO-2007124044 Nov 2007 WO
WO-2008106724 Sep 2008 WO
WO-2008150587 Dec 2008 WO
WO-2009099939 Aug 2009 WO
WO-2011072012 Jun 2011 WO
WO-2012142487 Oct 2012 WO
WO-2012148685 Nov 2012 WO
WO-2013068752 May 2013 WO
WO-2014011547 Jan 2014 WO
WO-2014059316 Apr 2014 WO
WO-2014194349 Dec 2014 WO
WO-2015154170 Oct 2015 WO
WO-2015154172 Oct 2015 WO
Non-Patent Literature Citations (204)
Entry
Ida, K. “Titanium for Medical and Dental Use”, Japanese journal of medical electronics and biological engineering, 24(1):47-54, 1986 (12 pages)—with English Summary.
“2002 Design & Engineering Awards, Portable Organ Preservation System”, Science (2002) (1 page).
“Celsior™ Cold Storage Solution”, Sangstat Medical Corporation (internet reference) (1999) (5 pages).
“History of Transplantation and Organ Preservation,” Barr Laboratories, Inc. (2004) (4 pages).
“Human heart beats on its own outside body”, USA Today (2001) (1 page).
“Human Heart Kept Alive Outside Body for First Time in Study of Portable Organ Preservation System™ at University of Pittsburgh Medical Center”, UPMC, McGowan Institute for Regenerative Medicine (2001) (2 pages).
“Machine Keeps Human Kidney Alive for 24-Hours”, American Academy of Anti-Aging Medicine, 222.worldhealth.net, Aug. 25, 2001, (<http://wwwworldhealth.net/p/393,1313.htm>) By Richard Klatz , Accessed Jul. 5, 2006 (1 page).
“Machine may be organ transplant breakthrough”, USA Today, by Stephen J. Carrera (<http://www.usatoday.com/news/health/2001-08-25-organ.htm>) (Aug. 5, 2001) (1 page).
“New discovery in organ transplantation”, MSNBC Chicago, No Author Listed (2001) (www.nbc5/com <http://www.nbc5/com>) (1 page).
“The Nation: Warm-Storage Device May Aid Organ Transplants”, Dow Jones Publications Library (2001) (1 page).
“ViaSpan (Belzer UW) Cold Storage Solution”, Barr Laboratories, Inc. (2002), 2 pages.
“Warm storage for donor organs”, University of Chicago Magazine (2001) (1 page).
Ahmad, N. et al., “A pathophysiologic study of the kidney tubule to optimize organ preservation solutions”, Kidney International 66(1):77-90 (2004), 14 pages.
Aitchison, et al., “Functional Assessment of Non-Heart-Beating Donor Lungs: Prediction of Post-Transplant Function”, European Journal of Cardio-thoracic Surgery, 20:187-194 (2001).
Aitchison, J.D. et al., “Nitric Oxide During Perfusion Improves Posttransplantation Function of Non-Heart-Beating Donor Lungs”, Transplantation, 75(12):1960-1964, Jun. 27, 2003, 5 pages.
Anathaswamy, A., “Machine keeps organs alive for longer”, NewScientist.com, Aug. 16, 2001, (<http://www.newscientist.com/article.ns?id=dn1168&print=true> (1 page).
Aoki, M. et al., Anti-CD18 Attenuates Deleterious Effects of Cardiopulmonary Bypass and Hypothermic Circulatory Arrest in Piglets, J. Card. Surg. 10(Suppl):407-17 (1995) (11 pages).
Bando, K. et al., “Oxygenated perfluorocarbon, recombinant human superoxide dismutase, and catalase ameliorate free radical induced myocardial injury during heart preservation and transplantation”, J. Thorac Cardiovasc Surg. 96:930-8 (Dec. 1988), 9 pages.
Barinov, E.F., “Hormonal-metabolic disturbances during biological preservation of the heart”, Fiziologicheskii Zhurnal (Kiev), 29(3):293-299 (1983) (8 pages)—Russian Language with English Abstract.
Belzer, F.O., “Formula for Belzer MPS Solution”, University of Wisconsin-Madison Organ Preservation, (<http://www.surgery.wisc.edu/transplat/research/southard/BelzerMPS.shtml>) (Oct. 3, 2003) (2 pages).
Benichou, J. et al., “Canine and Human Liver Preservation for 6 to 18 HR by Cold Infusion”, Transplantation, 24(6):407-411 (Dec. 1977) (5 pages).
Birkett, D. et al., “The Fatty Acid Content and Drug Binding Characteristics of Commercial Albumin Preparations”, Clinica Chimica Acta 85:253-258 (1978), 6 pages.
Blanchard, J.M. et al., “Techniques for Perfusion and Storage of Heterotopic Heart Transplants in Mice”, Microsurgery, 6:169-174 (1985), 6 pages.
Boggi, U. et al., “Pancreas Preservation with University of Wisconsin and Celsior Solutions”, Transplant Proceedings 36(3):563-565 (2004), 3 pages.
Boggi, U. et al., “Pancreas Preservation With University of Wisconsin and Celsior Solutions: A Single-Center, Prospective, Randomized Pilot Study”, Transplantation 27:77(8):1186-1190 (2004), 5 pages.
Botha, P., “Extended Donor Criteria in Lung Transplantation”, Current Opinion in Organ Transplantation, 14:206-210, 2009 (5 pages).
Boyle, E.M. Jr. et al., “Ischemia-Reperfusion Injury”, Ann. Thorac. Surg. 64:S24-S30 (1997), 7 pages.
Brandes, H. et al. “Influence of High Molecular Dextrans on Lung Function in an ex Vivo Porcine Lung Model,” Journal of Surgical Research, 101:2, 225-231 (2001) (7 pages).
Brasile, L. et al., “Organ Preservation Without Extreme Hypothermia Using an Oxygent™ Supplemented Perfusate”, Art. Cells, Blood Subs., and Immob. Biotech., 22(4):1463-68 (1994), 6 pages.
Burt, J.M. et al, “Myocardial function after preservation for 24 hours”, J. Thorac. Cardiovasc Surg., 92(2):238-46 (1986), 9 pages.
Calhoon, J.H. et al., “Twelve-Hour Canine Heart Preservation With A Simple, Portable Hypothermic Organ Perfusion Device”, Ann. Thorac. Surg., 62:91-3 (1996), 3 pages.
Canelo R. et al., “Experience with Hystidine Tryptophan Ketoglutarate Versus University Wisconsin Preservation Solutions in Transplantation”, Int. Surg. 88(3):145-51 (2003), 8 pages.
Carrier, B., “Chapter 4: Hypoxia and Oxygenation”, Alaska Air Medical Escort Training Manual, Fourth Edition, pp. 71-82, 2006, 12 pages.
Chambers, D.J. et al., “Long-Term Preservation of the Heart: The Effect of Infusion Pressure During Continuous Hypothermic Cardioplegia”, The Journal of Heart and Lung Transplantation, 11(4):665-75 (1992), 11 pages.
Chen, F. et al., “Development of New Organ Preservation Solutions in Kyoto University”, Yonsei Medical Journal, 46(6):1107-40 (2004), 8 pages.
Chien, S. et al., “A simple technique for multiorgan preservation”, The Journal of Thoracic and Cardiovascular Surgery, 95(1):55-61 (1988), 7 pages.
Chien, S. et al., “Canine Lung Transplantation After More than Twenty-four Hours of Normothermic Preservation”, The Journal of Heart and Lung Transplantation, 16:340-51 (1997), 12 pages.
Chien, S. et al., “Functional Studies of the Heart During a 24-Hour Preservation Using a New Autoperfusion Preparation”, The Journal of Heart and Lung Transplantation, 10(3):401-8 (1991), 8 pages.
Chinchoy, Edward Cheng-wey; “The Development, Refinement, and Uses of a Physiologically Working Isolated Ex Vivo Swine Heart Model”, A thesis submitted to the Faculty of the Graduate School of athe University of Minnesota, Dec. 1999 (136 pages).
Christophi, C. et al., “A Comparison of Standard and Rapid Infusion Methods of Liver Preservation During Multi-Organ Procurement”, Aust. N.Z.J. Surg., 61(9):692-694 (1991), 3 pages.
Cimino, Adria, “Doctor develops device to preserve donated organs”, Mass High Tech (2001), 2 pages.
CNN.com, “Heart kept beating outside body”, Associated Press CNN News Health Section (Oct. 7, 2001, 02:59) (CNN.com/Health with WebMD.com), 2 pages.
Collins, B.H., “Organ Transplantation: What Is the State of the Art?”, Annals of Surgery, 238(6 Suppl):S72-S89 (2003), 18 pages.
Cronin, D.C. et al., “Chapter 21: Liver Transplantation at The University of Chicago”, Clinical Transplants 231-238 (1999), 9 pages.
Daemen, J.H.C. et al., “Short-term outcome of kidney transplants from non-heart-beating donors after preservation by machine perfusion”, Transpl. Int. 9(Supp 1):S76-S80 (1996), 5 pages.
Definition of Examine, Merriam-Webster Dictionary on-line. www.merriam-webster.com/dictionary/examine, Printed Feb. 9, 2011, (1 page).
Demertzis, S. et al., “University of Wisconsin Versus St. Thomas' Hospital Solution for Human Donor Heart Preservation”, Ann Thorac Surg 55:1131-7 (1993), 7 pages.
Den Butter, G. et al., “Comparison of solutions for preservation of the rabbit liver as tested by isolated perfusion”, Transpl. Int. 8(6):466-471 (1995), 6 pages.
Denham, B.S. et al., “Twenty-Four Hour Canine Renal Preservation By Pulsatile Perfusion, Hypothermic Storage, and Combinations of the Two Methods”, Transplantation Proceedings, 9(3):1553-1556 (1977), 4 pages.
Dobrian, A. et al., “In vitro formation of oxidatively-modified and reassembled human low-density lipoproteins: antioxidant effect of albumin”, Biochimica et Biophysica Acta (BBA) 1169:12-24 (1993), 13 pages.
Drexler, H. et al., “Effect of L-arginine on coronary endothelial function in cardiac transplant recipients. Relation to vessel wall morphology,” Circulation 89(4):1615-1623 (1994) (10 pages).
Egan, T. M. et al., “Ex Vivo Evaluation of Human Lungs for Transplant Suitability”, Ann Thorac Surg, vol. 81, No. 4, pp. 1205-1213 (Apr. 2006) (9 pages).
Eiseman, B. et al., “A disposable liver perfusion chamber”, Surgery 60(6):1183-1186 (1966), 4 pages.
Engelman, R.M. et al., “Influence of Steroids on Complement and Cytokine Generation After Cardiopulmonary Bypass”, Ann Thorac Surg 60(3):801-04 (1995) (4 pages).
European Search Report for European Patent Application No. 08795820.3 dated Apr. 17, 2014 (6 pages).
European Search Report for European Patent Application No. 09707471.0 dated May 27, 2014 (7 pages).
European Search Report issued in EP12770852.7, dated Sep. 23, 2014, 8 pages.
Extended European Search Report issued in EP15803127.8, dated May 22, 2018 (14 pages).
Extended European Search Report issued in European Application No. 17172411.5, dated Nov. 8, 2017 (7 pages).
Fabregas, Luis, “UPMC tests machine to aid heart transplants”, Pittsburg Tribune-Review (Feb. 24, 2002), (<http://www.pittsburghlive.com/x/pittsburghrib/print_19181.html>), 2 pages.
Faggian, G. et al., “Donor Organ Preservation in High-Risk Cardiac Transplantation”, Transplantation Proceedings 36:617-619 (2004), 3 pages.
Featherstone, R.L. et al. “Comparison of Phosphodiesterase Inhibitors of Differing Isoenzyme Selectivity Added to St. Thomas' Hospital Cardioplegic Solution Used for Hypothermic Preservation of Rat Lungs”, Am J Respir Crit Care Med, Mar. 2000,162(3):850-856 (7 pages).
Fehrenberg, C. et al., “Protective Effects of B2 Preservation Solution in Comparison to a Standard Solution (Histidine-Tryptophan-Ketoglutarate/Bretschneider) in a Model of Isolated Autologous Hemoperfused Porcine Kidney”, Nephron Physiol 96:52-58 (2004) (7 pages).
Ferrera, R. et al., “Comparison of Different Techniques of Hypothermic Pig Heart Preservation”, Ann Thorac Surg 57(5):1233-1239 (1994), 7 pages.
File History for U.S. Appl. No. 60/616,835, filed Oct. 7, 2004 (82 pages).
File History for U.S. Appl. No. 60/694,971, filed Jun. 28, 2005 (280 pages).
File History for U.S. Appl. No. 60/725,168, filed Oct. 6, 2005 (699 pages).
Finn, A. et al., “Effects of Inhibition of Complement Activation Using Recombinant Soluble Complement Receptor 1 on Neutrophil CD11B/CD18 and L-Selectin Expression and Release of Interleukin-8 and Elastase in Simulated Cardiopulmonary Bypass”, J Thorac Cardiovasc Surg 111(2):451-459 (1996), 9 pages.
Fourcade, C. et al., “Nouvelle Méthode De Conservation Du Rein Avec Une Solution De Collins”, <<A New Method of Kidney Preservation with Collins' Solution,>> Biomed. 21(7):308-11 (1974), English Abstract, 5 pages.
Fraser, C.D. Jr. et al., “Evaluation of Current Organ Preservation Methods for Heart-Lung Transplantation”, Transplantation Proceedings, 20(1 Suppl. 1):987-990 (1988), 4 pages.
Glucose, The Merck Index, 11th ed. Entry 4353 (pp. 699-700) (1989), 3 pages.
Grynberg, A. et al., “Fatty Acid Oxidation in the Heart”, Journal of Cardiovascular Pharmacology, 28(Suppl. 1):S11-S17 (1996) (8 pages).
Guarrera, J.V. et al., “Pulsatile Machine Perfusion With Vasosol Solution Improves Early Graft Function After Cadaveric Renal Transplantation”, Transplantation 77(8):1264-1268 (2004), 5 pages.
Gundry, S.R. et al., “Successful Transplantation of Hearts Harvested 30 Minutes After Death From Exsanguination”, Ann Thorac Surg 53(5):772-775 (1992), 4 pages.
Habazetti, H. et al., “Improvement in Functional Recovery of the Isolated Guinea IG Heart After Hyperkalemic Reperfusion With Adenosine”, J Thorac Cardiovasc Surg 111(1):74-84 (1996) (11 pages).
Hachida, M. et al., Abstract “Efficacy of myocardial preservation using HTK solution in continuous 120 min cross-clamping method—a comparative study with GIK method”, Nippon Kyobu Geka Gakkai Zasshi. 41(9):1495-1501 (1993), 1 page.
Hardesty, R.L. et al., Original Communications, “Autoperfusion of the heart and lungs for preservation during distant procurement”, J Thorac Cardiovasc Surg, 93:11-18 (1987) (8 pages).
Hartman, J.C., “The Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of ACE Inhibitors”, Ann Thorac Surg 60:789-792 (1995), 4 pages.
Hassanein, W.H. et al., “A Novel Approach for 12 Hour Donor Heart Preservation, Presented at the 70th Scientific Sessions of The American Heart Association”, Abstract was published in Circulation (1997), 1 page.
Hassanein, W.H. et al., “Continuous Perfusion of Donor Hearts in the Beating State Extends Preservation Time and Improves Recovery of Function”, The Journal of Thoracic and Cardiovascular Surgery, pp. 821-830 (1998), 10 pages.
Heil, J.E. et al., “A Controlled Comparison of Kidney Preservation by Two Methods: Machine Perfusion and Cold Storage”, Transplantation Proceedings 19(1):2046 (1987), 1 page.
Howarth, F.C. et al., “Effects of extracellular magnesium and beta adrenergic stimulation on contractile force and magnesium mobilization in the isolated rat heart”, Magnesium Research, 7:187-197, 1994 (13 pages).
Hülsmann, W.C et al., “Loss of cardiac contractility and severe morphologic changes by acutely lowering the pH of the perfusion medium: protection by fatty acids”, Bragen 20256, Biochimica et Biophysica Acta., 1033:214-218 (1990) (5 pages).
Imber, C. et al., “Advantages of Normothermic Perfusion Over Cold Storage in Liver Preservation”, Transplantation, 73(5):701-709 (2002), 9 pages.
International Search Report and Written Opinion for International Application No. PCT/US2012/033626 dated Sep. 20, 2012 (12 pages).
International Search Report and Written Opinion issued by the U.S. Patent and Trademark Office as Searching Authority, in International Application No. PCT/US16/50512, dated Dec. 12, 2016 (9 pages).
International Search Report, issued by the European Patent Office as Searching Authority, in PCT/US07/009652 International Search Report, dated Apr. 18, 2008, 5 pages.
International Search Report, issued by the European Patent Office as Searching Authority, issued in PCT/US98/19912, dated May 3, 1999 (4 pages).
International Search Report, issued by the U.S. Patent Office as Searching Authority, issued in PCT/US08/61454 International search report dated Dec. 5, 2008 (2 pages).
International Search Report, issued by the U.S. Patent Office as Searching Authority, issued in PCT/US09/032619, dated Jun. 4, 2009 (4 pages).
Janßen, H. et al., “UW is Superior to Celsior and HTK in the Protection of Human Liver Endothelial Cells Against Preservation Injury”, Liver Transplantation, 10(12):1514-1523 (2004), 10 pages.
Johnson, Kerry et al, “POPS: Portable Organ Preservation System”, UPMC Health System and TransMedics, Inc. (No date) (1 page).
Johnston, R., “What's Normal About DLCO?”, PFT Blog, Jan. 1, 2014 (17 pages).
Kawakami, et al., “Successful Preservation of the Isolated Canine Heart for 24 Hours by Low Pressure—Low Temperature Continuous Perfusion”, Japanese Annals of Thoracic Surgery, Japan, 7(6):543-547, Dec. 25, 1987 (13 pages)—English Translation.
Kawamura, T. et al., “Long-Term Preservation of Canine Pancreas by a New Simple Cold Storage Method Using Perfluorochemical—The Two-Layer Cold Storage Method (Euro-Collins' Solution/Perfluorochemical)-”, Kobe J. Med. Sci., 38(2):135-145 (1992), 11 pages.
Kelly, R.F., “Current strategies in lung preservation”, J. Lab Clin Med, 136:427-440 (2000), 14 pages.
Keshavjee, S.H. et al., “A method for safe twelve-hour pulmonary preservation”, J Thorac Cardiovasc Surg, 98:529-534 (1989), 6 pages.
Kioka, Y. et al., “Twenty-Four-Hour Isolated Heart Preservation by Perfusion Method With Oxygenated Solution Containing Perfluorochemicals and Albumin”, The Journal of Heart Transplantation, 5:437-443 (1986), 7 pages.
Koike, et al., “An Experimental Study on the Hypothermic Preservation of the Rabbit Heart Using Glucose-Insulin-Potassium Solution—Intermittent Perfusion Method Versus Simple Immersion Method”, Japanese Annals of Thoracic Surgery, 7(6):527-532, Dec. 25, 1987 (16 pages)—English Translation.
Kozaki, K. et al., “Usefulness of a Combination of Machine Perfusion and Pentoxifylline for Porcine Liver Transplantation From Non-Heart-Beating Donors With Prolonged Hypotension”, Transplantation Proceedings, 29:3476-3477 (1997), 2 pages.
Kubono, K. et al., “Examination of Plasma and Corpuscle Adenosine Concentration in Normal Subject by Radioimmunoassay”, Rinshou Kagaku (Clinical Chemistry, 20(2):72-77, Jun. 1991 (6 pages)—Japanese Language.
Kuroda, Y. et al., “A New, Simple Method for Cold Storage of the Pancreas Using Perfluorochemical”, Transplantation, 46(3):457-460 (1988), 4 pages.
Lasley, R.D. et al., “Protective Effects of Adenosine in the Reversibly Injured Heart”, Ann Thorac Surg, 60(3):843-846 (1995), 4 pages.
Lawrence, C., “Machine preserves organs outside body,” Chicago Sun Times (2001), 1 page.
Lefer, A.M., “Attenuation of Myocardial Ischemia-Reperfusion Injury With Nitric Oxide Replacement Therapy”, Ann Thorac Surg 60(3):847-851 (1995), 5 pages.
Li, G. et al., “Functional Recovery in Rabbit Heart after Preservation with a Blood Cardioplegic Solution and Perfusion,” J Heart Lung Transplant, 12(2)263-270 (1993) (8 pages).
Li, X. et al., “Insulin in University of Wisconsin Solution Exacerbates the Ischemic Injury and Decreases the Graft Survival Rate in Rat Liver Transplantation”, Transplantation, 15:76(1):44-49 (2003), 6 pages.
Li, X. et al., “Insulin in UW Solution Exacerbates Hepatic Ischemia / Reperfusion Injury by Energy Depletion Through the IRS-2 / SREBP—1c Pathway”, Liver Transplantation, 10(9):1173-1182 (2004), 10 pages.
Liu,J. et al., “Annexin V Assay-proven Anti-apopototic Effect of Ascorbic Acid 2-glucoside after Cold Ischemia/Reperfusion Injury in Rat Liver Transplantation”, Acta Med. Okayama, 57(5):209-216 (2003), 8 pages.
Macchiarini, P. et al. “Ex Vivo Lung Model of Pig-to-Human Hyperacute Xenograft Rejection”, The Journal of Thoracic and Cardiovascular Surgery, 114:3, 315-325 (2000) (11 pages).
Mankad, P. et al., “Endothelial dysfunction caused by University of Wisconsin preservation solution in the rat heart”, J Thorac Cardiovasc Surg 104(6): 1618-1624 (1992), 7 pages.
Matsuno, N. et al., “Effectiveness of Machine Perfusion Preservation as a Viability Determination Method for Kidneys Procured from Non-Heart-Beating Donors,” Transplantation Proceedings, 26(4):2421-2422 (1994) (2 pages).
Matsuno, N. et al., “The Effect of Machine Perfusion Preservation Versus Cold Storage on the Function of Kidneys From Non-Heart-Beating Donors”, Transplantation, 57(2):293-294 (1994) (2 pages).
Menasché, P. et al., “Experimental evaluation of Celsior®, a new heart preservation solution,” Eur J Cardio-thorac Surg 8:207-213 (1994), 7 pages.
Menasché, P. et al., “Improved recovery of heart transplants with a specific kit of preservation solutions,” The Journal of Thoracic and Cardiovascular Surgery, 105(2):353-363 (1993), 11 pages.
Menasché, P., “The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function”, Current Opinion in Cardiology, 10:597-604 (1995) (8 pages).
Moisiuk, Y. et al., “Histidine-Tryptophan-Ketoglutarate Versus Euro-Collins for Preservation of Kidneys From Non-Heart-Beating Donors”, Transplantation Proceedings, 28(1):202 (1996) (1 page).
Moller-Pedersen, T. et al., “Evaluation of potential organ culture media for eye banking using human donor corneas”, Br J Ophthamol, 85(9):1075-1079 (2001), 5 pages.
Morimoto, T. et al., “A Simple Method for Extended Heart-Lung Preservation by Autoperfusion”, Trans Am Soc Artif Intern Organs, 30:320-324 (1984), 5 pages.
Nicholson, M.L. et al., “A Comparison of Renal Preservation by Cold Storage and Machine Perfusion Using a Porcine Autotransplant Model”, Transplantation 78(3):333-337 (2004), 5 pages.
No Author Listed, “Custodiol® HTK Solution for Multi-Organ Protection”, Saudi Center for Organ Transplantation, Date Unknown, originally cited to U.S. Patent Office Jun. 30, 2014, in U.S. Appl. No. 12/892,451 (2 pages).
No Author Listed, “SOLTRAN Kidney perfusion fluid”, Baxter, No Month Listed—2001-2004 (1 page).
No Author Listed, “The comprehensive resource for physicians, drug and illness information”, VIASPAN™ DuPont Pharma Cold Storage Solution, Date Unknown (3 pages).
No Author Listed, “UW Solution Composition”, DuPont Pharmaceutical, Date Unknown (1 page).
No Author Listed. “Custodiol HTK” Physicians' Desk Reference, 57th Edition, Thomson PDR. ISBN:1-56363-445-457. No Month Listed—2003 (3 pages).
Odagiri, S. et al., “Pusatile Assist Device: New Pulsatile Pump Using Pulsatile Assist Device-Hemodynamic Comparison of Pulsatile V-A Bypass (VABP), Pulsatile Left Heart Bypass (LHBP) and Constant Flow Left Heart Bypass (LHB)”, Journal of Japan Surgical Society, 83(6):515-523, Jun. 1982, 12 pages—English Abstract.
Opelz, G. et al., “Advantage of Cold Storage Over Machine Perfusion for Preservation of Cadaver Kidneys”, Transplantation, 33(1):64-68 (1982), 5 pages.
Opelz, G. et al., “Comparative Analysis of Kidney Preservation Methods”, Transplantation Proceedings 28(1):87-90 (1996), 4 pages.
Ota, K. et al., “Artificial Organ”, Current State and Future of Substitution of Functions, pp. 150-151, 1983 (7 pages)—English Translation.
Pearl, J.M. et al., Loss of endothelium-dependent vasodilatation and nitric oxide release after myocardial protection with University of Wisconsin solution, Cardiovascular Surgery 107(1):257-264 (1994) (8 pages).
Petrovsky, B.V. et al., “Justification and Application of a New Method for Transorganic Oxygen Preservation of the Kidneys”, Vestn. Akad. Med. Nauk, SSSR., (2):69-82 (1989)—English Abstract, 15 pages.
Pinsky, D. et al., “Restoration of the cAMP Second Messenger Pathway Enhances Cardiac Preservation for Transplantation in a Heterotopic Rat Model”, J. Clin. Invest. 92(6):2944-3002 (1993) (9 pages).
Ploeg, R.J. et al., “Successful 72-Hour Cold Storage of Dog Kidneys With UW Solution”, Transplantation, 46(2):191-196 (1988), 6 pages.
Pokorny, H. et al., “Histidine-tryptophan-ketoglutarate solution for organ preservation in human liver transplantation—a prospective multi-centre observation study”, Transpl Int 17(5):256-260 (2004), (5 pages).
Poston, R.S. et al., “Optimizing Donor Heart Outcome After Prolonged Storage With Endothelial Function Analysis and Continuous Perfusion”, Ann Thorac Surg, 78:1362-1370, 2004 (9 pages).
Potdar, S. et al., “Initial experience using histidine-tryptophan-ketoglutarate solution in clinical pancreas transplantation”, Clin Transplant, 18(6):661-665 (2004), 5 pages.
Pozniak, A., “Keeping Hearts Alive Doctors Develop a High-Tech System to Salvage Donated Organs”, ABC News.com, (Dec. 7, 2001) (<http://abcnews.go.com/print?id=117085>), (2 pages).
Probst, R. et al. “Carbohydrate and fatty acid metabolism of cultured adult cardiac myocytes”, Am. J. Physiol. 250 (Heart, Circ. Physiol. 19):H853-H860 (1986) (8 pages).
Pruitt, “Pharmacological Treatment of Respiratory Disorders”, RT Magazine, http://www.rtmagazine.com/2007/05/pharmacological-treatment-of-respiratory-disorders, May 3, 2007, accessed Jan. 1, 2019 (6 pages).
Rao, V. et al., “Donor Blood Perfusion Improves Myocardial Recovery After Heart Transplantation”, J. Heart Lung Transplant. 16(6):667-673 (1997) (7 pages).
Reddy, S.P. et al., “Preservation of Porcine Non-Heart-Beating Donor Livers by Sequential Cold Storage and Warm Perfusion”, Transplantation, 77(9):1328-1332 (2004), 5 pages.
Richens, D. et al., “Clinical Study of Crystalloid Cardiplegia vs Aspartate-Enriched Cardioplegia Plus Warm Reperfusion for Donor Heart Preservation”, Transplantation Proceedings 24(1): 1608-1610 (1993) (3 pages).
Rinder, C.S. et al., “Blockade of C5a and C5b-9 Generation Inhibits Leukocyte and Platelet Activation during Extracorporeal Circulation”, J. Clin. Invest. 96:3(1564-1572) 1995 (9 pages).
Rosenkranz, E.R., “Substrate Enhancement of Cardioplegic Solution: Experimental Studies and Clinical Evaluation”, Ann Thorac Surg 60:797-800 (1995) (4 pages).
Rossi, L. et al., “Innovations-report: New organ preservation solution easier to use”, (<http://www.innovations-report.com/html/reports/medicine_report-18854.html>), Feb. 6, 2003 (2 pages).
Rossi, L., “Portable Organ Preservation System™ Keeps Human Heart Alive Outside Body”, PITT Campaign Chronicle (Oct. 7, 2001), 2 pages.
Schmid, T. et al., “The Use of Myocytes as a Model for Developing Successful Heart Preservation Solutions”, Transplantation 52(1):20-26 (Jul. 1991) (7 pages).
Schon, M.R. et al., “Liver Transplantation After Organ Preservation With Normothermic Extracorporeal Perfusion”, Annals of Surgery 233(1):114-123 (2001), 10 pages.
Schwalb, H. et al., “New Solution for Prolonged Myocardial Preservation for Transplantation”, The Journal of Heart and Lung Transplantation 17(2):222-229 (1998), 8 pages.
Seccombe, J.F. et al., “Coronary Artery Endothelial Function After Myocardial Ischemia and Reperfusion”, Ann Thorac Surg 60(3):778-788 (1995), 11 pages.
Segel, L.D. et al., “Posttransplantation Function of Hearts Preserved with Fluorochemical Emulsion”, J Heart Lung Transplant, 13(4):669-680 (1994), 12 pages.
Segel,L.D. et al., “Recovery of Sheep Hearts After Perfusin Preservation or Static Storage with Crystalloid Media”, The Journal of Heart and Lung Transplantation, 17:211-221 (1998) (11 pages).
Sekine, M. et al., “Effect of Obese and Aging on Blood Fatty Acid Consumption in Japanese”, Bulletin of the Graduate School of Human Life Science, Showa Women's University, 4:63-70, 1995 (8 pages)—English Abstract.
Semat, H. and Katz, R., “Physics, Chapter 9: Hydrodynamics (Fluids in Motion)”, Hydrodynamics. University of Nebraska—Lincoln. Pap143. No Month Listed 1958 (18 pages).
Shimokawa, S. et al., “A New Lung Preservation Method of Topical Cooling by Ambient Cold Air Combined with High-Frequency Oscillation: An Experiemental Study”, Transplantation Proceedings, 26(4):2364-2366 (1994) (3 pages).
Shimokawa, S. et al., “A New Lung Preservation Method of Topical Cooling by Ambient Cold Air: An Experimental Study”, Transplantation Proceedings, 23 (1):653-654 (1991) (2 pages).
Shirakura, R. et al., “Multiorgan Procurement from Non-Heart-Beating Donors by use of Osaka University Cocktail, Osaka Rinse Solution, and the Portable Cardiopulmonary Bypass Machine”, Transplantation Proceedings, 25(6):3093-3094 (1993) (2 pages).
Southard, J., “The Right Solution for Organ Preservation”, Business Briefings: Global Surgery 79-84 (2004) (6 pages).
Steen, S. et al., “Transplantation of lungs from non-heart-beating donors after functional assessment ex vivo”, Ann Thorac Surg, 76:244-252, 2003, 11 pages.
Stubenitsky, B.M. et al., “Kidney preservation in the next millenium”, Transpl Int, 12:83-91 (1999), 9 pages.
Sunamori, M. et al., “Relative Advantages of Nondepolarizing Solution to Depolarizing University of Wisconsin Solution in Donor Heart Preservation”, Transplantation Proceedings, 25(1): 1613-1617 (1993), 5 pages.
Synchrony Definition, http://dictionary.reference.com/browse/synchrony, Random House Unabridged Dictionary, 2006 (1 page).
Tang, D.G. et al., “Warm Ischemia Lung Protection With Pinacidil: An ATP Regulated Potassium Channel Opener”, Ann Thorac Surg, 76:385-390 (2003), 6 pages.
Tesi, R.J. et al., Pulsatile Kidney Perfusion for Preservation and Evaluation: Use of High-Risk Kidney Donors to Expand the Donor Pool, Transplantation Proceedings, 25(6):3099-3100 (1993) (2 pages).
Turpin, B.P. et al., “Perfusion of Isolated Rat Adipose Cells”, The Journal of Clinical Investigation, 60:442-448 (1977), 7 pages.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research, “Drugs@FDA—Solu-Medrol: Label and Approval History”, (Available online at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist . . .), accessed Feb. 9, 2010 (3 pages).
U.S. Food and Drug Administration, Center for Drug Evaluation and Research, “Drugs@FDA—Solu-Medrol: Drug Details”, (Accessible online at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails . . .), accessed Feb. 9, 2010 (1 page).
Vinten-Johansen, J. et al., “Reduction in Surgical Ischemic-Reperfusion Injury With Adenosine and Nitric Oxide Therapy”, Ann Thorac Surg 60(3):852-857 (1995), 6 pages.
Voiglio, E. et al. “Rat Multiple Organ Blocks: Microsurgical Technique of Removal for Ex Vivo Aerobic Organ Preservation Using a Fluorocarbon Emulsion”, Microsurgery 20:3, 109-115 (2000) (7 pages).
Watanabe, S. et al., “Effects of free fatty acids on the binding of bovine and human serum albumin with steroid hormones”, Biochimica et Biophysica Acta (BGBA), 1289:385-396 (1996), 12 pages.
Wei, Z., et al., “A Study on the Preservation of Rat Kidney with HX-III Solution”, J WCUMS, 31(3):347-349 (2000)—English Abstract, 4 pages.
Wicomb, W. et al., “Orthotopic transplantation of the baboon heart after 20 to 24 hours' preservation by continuous hypothermic perfusion with an oxygenated hyperosmolar solution”, J. Thorac Cardiovasc Surg, 83(1):133-140 (1982), 8 pages.
Wicomb, W.N. et al., “24-Hour Rabbit Heart Storage With UW Solution”, Transplantation, 48(1):6-9 (1989), 4 pages.
Wicomb, W.N. et al., “Cardiac Transplantation Following Storage of the Donor Heart by a Portable Hypothermic Perfusion System”, The Annals of Thoracic Surgery, 37(3):243-248 (1984), 6 pages.
Wright, N. et al. “A porcine ex vivo paracorporeal model of lung transplantation”, Laboratory Animals Ltd. Laboratory Animals, 34:1, 56-62 (2000) (7 pages).
Yang, et al., “Effect of Hypoxia and Reoxygenation on the Formation and Release of Reactive Oxygen Species by Porcine Pulmonary Artery Endothelial Cells”, Journal of Cellular Physiology, 164:414-423 (1995) (10 pages).
Yeung, J., et al., “Physiologic assessment of the ex vivo donor lung for transplantation”, Journal of Heart and Lung Transplantation, 31(10):1120-1126, Oct. 2012 (7 pages).
Yland, M.J. et al., “New Pulsatile Perfusion Method for Non-Heart-Beating Cadaveric Donor Organs: A Preliminary Report”, Transplantation Proceedings, 25(6):3087-3090 (1993), 4 pages.
Yokoyama, H. et al., “Isolated Dog Hearts Prepared in Cold Tyrode Solution and Reperfused with Arterial Blood Are Functionally and Ultrastructurally Normal”, The Tohoku Journal of Experimental Medicine, 156:121-134, 1988 (14 pages).
Zhang, Z. et al., “Research Progress on Preservation of Severed Limbs”, Chinese Journal of Reparative and Reconstructive Surgery, 14(3):189-192 (2000)—English Abstract, 8 pages.
Chen, E. P. et al., “Milrinone Improves Pulmonary Hemodynamics and Right Ventricular Function in Chronic Pulmonary Hypertension”, Ann Thorac Surg, 63:814-821, 1997 (8 pages).
Duarte, J.D. et al., “Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics”, Future Cardiol., 9(3):335-349, 2013 (15 pages).
Givertz, M.M. et al., “Effect of Bolus Milrinone on Hemodynamic Variables and Pulmonary Vascular Resistance in Patients With Severe Left Ventricular Dysfunction: A Rapid Test for Reversibility of Pulmonary Hypertension”, JACC, 28(7):1775-1780, Dec. 1996 (6 pages).
Han, B. et al., “Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease”, Experimental and Therapeutic Medicine, 16:1175-1186, 2018 (12 pages).
Hoeper, M.M. et al., “Intensive Care Unit Management of Patients with Severe Pulmonary Hypertension and Right Heart Failure”, Am J Respir Crit Care Med, 184:1114-1124, 2011 (11 pages).
Hui-Li, G. “The Management of Acute Pulmonary Arterial Hypertension”, Cardiovascular Therapeutics, 29:153-175, 2011 (23 pages).
Jaski, B.E. et al., “Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside”, J. Clin Invest., 75(2):643-649, 1985 (8 pages).
Lobato, E.B. et al., “Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension”, British Journal of Anaesthesia, 96(3):317-322, 2006 (6 pages).
Open Anesthesia—Milrinone: pharmacology, https://www.openanesthesia.org/milrinone_pharmacology/, accessed 2019 (3 pages).
Siobal, M.S. “Pulmonary Vasodilators”, Respir Care, 52(7):885-899, Jul. 2007 (15 pages).
Russell, H.E. et al., “An Evaluation of Infusion Therapy (Including Dextran) for Venous Thrombosis”, Circulation, 33:839-846, Jun. 1966 (8 pages).
Baker, L.E. et al., “Artificial Maintenance Media for Cell and Organ Cultivation”, Journal of Experimental Medicine, 70:29-38, Jul. 1, 1939 (15 pages).
Rao, M.V. et al., “Magnesium Sulfate: Chemical and Technical Assessment”, MgSO4 (CTA), 2007 (5 pages).
European Extended Search Report issued in EP 16844964.3, dated Apr. 26, 2019 (7 pages).
Saez, D.G. et al., “Evaluation of the Organ Care System in Heart Transplantation With an Adverse Donor/Recipient Profile”, Ann. Thorac. Surg., 98:2099-2106, 2014 (8 pages).
Sato, H. et al., “Supplemental L-Arginine During Cardioplegic Arrest and Reperfusion Avoids Regional Postischemic Injury”, J Thorac Cardiovasc Surg 110(2):302-314 (1995), (13 pages).
European Search Report issued for European Application No. EP19204566.4, dated May 25, 2020 (7 pages).
Gever, J., “Technique to Repair Damaged Donor Lungs for Graft Passes Clinical Test”, MedPage Today, https://www.medpagetoday.org/surgery/transplantation/12245, Accessed Jul. 11, 2020, dated Dec. 19, 2008 (4 pages).
Gohrbandt, B., et al., “Glycine intravenous donor preconditioning is superior to glycine supplementation to low-potassium dextran flush preservation and improves graft function in a large animal lung transplantation model after 24 hours of cold ischemia”, The Journal of Thoracic and Cardiovascular Surgery, 131(3):724-729, Mar. 2006 (6 pages).
Hai, Human Body Atlas, First Edition, Liaoning Science and Technology Publishing House, p. 120, Oct. 31, 2011 (3 pages)—with English Translation.
Keshavjee, S.H. et al., “The role of dextran 40 and potassium in extended hypothermic lung preservation for transplantation”, Journal of Thoracic and Cardiovascular Surgery, 103(2):314-325, Feb. 1992 (12 pages).
Wei, Y. et al., “Protective Effect of Specific Phosphodiesterase Inhibitor Milrinone for Donor Lungs”, Chinese Journal of New Drugs, 16(21):1762-1765, 2007—English Translation issued by U.S. Patent and Trademark Office, Aug. 2020 (17 pages).
Jirsch, D.W. et al., “Ex Vivo Evaluation of Stored Lungs”, The Annals of Thoracic Surgery, 10(2):163-168, Aug. 1970 (6 pages).
Venuta, F. et al., “History of lung transplantation”, Journal of Thoracic Disease, 9(12):5458-5471, Dec. 2017 (14 pages).
Related Publications (1)
Number Date Country
20190110466 A1 Apr 2019 US
Provisional Applications (1)
Number Date Country
62215825 Sep 2015 US
Continuations (1)
Number Date Country
Parent 15258194 Sep 2016 US
Child 16230580 US